Overview

Marketed as "topical Botox", which overstates it considerably. It does work by a related mechanism, and controlled studies do show measurable wrinkle-depth reduction — just far smaller than injectable neuromodulators.

Cosmetic IngredientWidely used cosmetic ingredient with published human topical studies. Not a drug; makes cosmetic rather than therapeutic claims.

At a glance

Regulatory status	Widely used cosmetic ingredient with published human topical studies. Not a drug; makes cosmetic rather than therapeutic claims.
Drug class	Synthetic hexapeptide modelled on the N-terminal end of SNAP-25
Route	Topical
Half-life	Not applicable — topical, non-systemic
Evidence rating	3/5 Moderate Evidence rating 3 out of 5: Moderate Small or early-phase human trials, or good controlled topical human data.
Studied in	Several controlled topical studies measuring wrinkle depth by profilometry and image analysis over 4–12 weeks.

How it works

Mimics the N-terminal of SNAP-25 and competes for a position in the SNARE complex required for vesicular acetylcholine release at the neuromuscular junction, modestly reducing muscle contraction. Botulinum toxin cleaves SNAP-25 outright, which is why the effect sizes differ so much.

Evidence base

Rated 3 of 5 — Moderate. Small or early-phase human trials, or good controlled topical human data.

Objective outcome measures, small effect sizes, significant industry funding.

Benefits & potential uses

Bars indicate how well each claim is supported: three = strong human evidence, two = moderate, one = preliminary or preclinical.

Measurable wrinkle-depth reduction Moderate evidence

Controlled studies report reductions on the order of 10–30% in expression-line depth over 4–8 weeks — modest but real and objectively measured.
Excellent safety profile Strong evidence

Topical, non-systemic, and very well tolerated across studies.
No injections or downtime Strong evidence

The practical appeal: no needles, no procedure, no recovery.
Compatible with most routines Moderate evidence

Water-soluble and stable in typical cosmetic formulations.

Risks, cons & cautions

Bars indicate seriousness: three = serious or common, two = moderate, one = minor.

Far weaker than injectable neuromodulators Minor

Comparing it to botulinum toxin sets expectations it cannot meet.
Limited skin penetration Moderate evidence

A hexapeptide crossing the stratum corneum in meaningful quantity is a genuine formulation challenge; delivery system matters enormously.
Effects reverse on stopping Minor

Continuous use is required to maintain any benefit.
Industry-funded evidence base Moderate evidence

Much of the supporting research comes from ingredient manufacturers.
Mild irritation in sensitive skin Minor

Uncommon and generally minor.

Who should avoid it

Known peptide or formulation ingredient allergy
Broken or irritated skin

If used under medical supervision, monitor

None required

Regulatory & legal status

Lawful cosmetic ingredient in the US, EU and most markets.

Infographic

Argireline (Acetyl Hexapeptide-8) — benefits & risks at a glance Download SVG

Where to read further

We link to live literature searches rather than a frozen citation list, so you always see current results — including anything published after our last review.

skinwrinklestopicalcosmeticSNAP-25

Related peptides in Skin & Cosmetic

Terms used on this page

Effect Size: Effect size is the magnitude of a difference or an association, expressed on a scale that does not depend on how many participants were studied, unlike a p-value.
N-Terminus: The N-terminus is the end of a peptide chain bearing a free alpha-amino group, the point from which sequences are written and from which aminopeptidases and DPP-4 begin degrading the molecule.
Stratum Corneum: The stratum corneum is the outermost epidermal layer of dead, keratin-filled corneocytes in a lipid matrix, and it is the rate-limiting barrier for essentially every topical ingredient.

This page is educational information, not medical advice. It cannot account for your medical history, medications, or risk factors. Do not start, stop or change any treatment based on it. Speak to a qualified healthcare professional who knows your case.